Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS)
Jining, CN
Shandong Lukang Pharmaceutical Co.,Ltd., a Chinese enterprise, primarily focuses on the production and distribution of bio-pharmaceuticals and antibiotics. Their comprehensive product range features active pharmaceutical ingredients (APIs) and finished drug formulations for both human and veterinary use, alongside bio-pesticides, traditional herbal remedies, and amino acids. Beyond its core pharmaceutical operations, the company also engages in environmental management services, including wastewater treatment, odor control, and the maintenance of sewage facilities, as well as the manufacturing and sale of ecological protection materials. Established in 1966 as Jining Antibiotic Factory, the firm rebranded to its current name in October 1993. Headquartered in Jining, China, it maintains a global footprint, distributing its offerings to approximately 40 nations across Asia, Europe, Africa, and the United States.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.16% | -3.19% | -3.19% | -13.97% | -19.76% | -12.83% | -27.31% | +16.22% | +2.07% | +16.22% | +50.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-7.5% Q1'26: -3.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-72.7% Q1'26: -43.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.1% Q1'26: +7.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.9% Q1'26: +4.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.1% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.4% Q1'26: +19.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.25× ★ Q1'26: 9.67× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
3.33B
est: 3.39B (-1.7%)
|
3.73B
est: 3.82B (-2.2%)
|
| EBITDA |
317.21M
est: 333.64M (-4.9%)
|
330.41M
est: 376.07M (-12.1%)
|
| EBIT |
159.28M
est: 124.74M (+27.7%)
|
143.47M
est: 140.60M (+2.0%)
|
| Net Income |
161.39M
|
121.25M
|
| SGA |
626.63M
est: 452.00M (+38.6%)
|
687.94M
est: 509.48M (+35.0%)
|
| EPS |
0.19
|
0.14
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 309.1K | 0.06% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 40.1K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 180.5K | 0.39% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 8.7K | 0.44% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 109.7K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 109.7K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.7K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 19.6K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 967.6K | 0.06% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.8K | 0.10% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bao Kun Jing | Board Secretary | — | male |
| Defeng He | Deputy General Manager | — | male |
| Haifeng Cao | Deputy General Manager | — | male |
| Jing Zhang | Finance Director & Director | — | female |
| Kun Dong | GM & Director | — | male |
| Su Juan Yang | Deputy General Manager | — | female |
| Zhang Jing | Finance Director & Director | — | female |
| Zhi Gang Jin | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600789.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
